Advertisement

Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients

      Abstract

      The association of variants of the gene encoding methionine synthase reductase (MTRR) with hyperhomocysteinemia, folate and Vitamin B12 status in kidney graft recipients is unknown.
      We examined two mutations in MTRR in a cross-sectional study of 733 kidney graft recipients.
      The allele frequency of MTRR 66G was 0.55. 369 patients (50.3%) were heterozygous and 219 patients (29.9%) were homozygous for the mutation. None of the patients showed the 997C>G mutation. The allelic variants of MTRR 66A>G showed no significant association with total homocysteine (tHcy) levels, both in univariate analyses, and in a multivariate model controlling for age, gender, body mass index, renal function, time since transplantation, underlying kidney disease, as well as the MTHFR 677C>T/1298A>C genotypes. Similarly, no significant associations between the MTRR 66A>G genotypes and plasma folate or Vitamin B12 levels were found.
      In conclusion, MTRR 66A>G has no major effect on tHcy, folate, or Vitamin B12 plasma concentrations in kidney graft recipients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Födinger M.
        • Buchmayer H.
        • Sunder-Plassmann G.
        Molecular genetics of homocysteine metabolism.
        Miner Electrolyte Metab. 1999; 25: 269-278
        • Födinger M.
        • Hörl W.H.
        • Sunder-Plassmann G.
        Molecular biology of 5,10-methylenetetrahydrofolate reductase.
        J. Nephrol. 2000; 13: 20-33
        • Leclerc D.
        • Wilson A.
        • Dumas R.
        • et al.
        Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria.
        Proc. Natl. Acad. Sci. USA. 1998; 95: 3059-3064
        • Leclerc D.
        • Odievre M.H.
        • Wu Q.
        • et al.
        Molecular cloning, expression and physical mapping of the human methioine synthase reductase gene.
        Gene. 1999; 240: 75-88
        • Wilson A.
        • Leclerc D.
        • Rosenblatt D.S.
        • Gravel R.A.
        Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism.
        Hum Mol. Genet. 1999; 8: 2009-2016
        • Wilson A.
        • Platt R.
        • Wu Q.
        • et al.
        A common variant in methionine synthase reductase combined with low cobalamin (Vitamin B12) increases risk for spina bifida.
        Mol. Genet Metab. 1999; 67: 317-323
        • Sunder-Plassmann G.
        • Födinger M.
        Genetic determinants of the homocysteine level.
        Kidney Int. 2003; 63: S141-S144
        • Olteanu H.
        • Munson T.
        • Banerjee R.
        Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase.
        Biochemistry. 2002; 41: 13378-13385
        • Födinger M.
        • Buchmayer H.
        • Heinz G.
        • et al.
        Effect of MTHFR 1298A > C and MTHFR 677C > T genotypes on total homocysteine, folate, and Vitamin B12 plasma concentrations in kidney graft recipients.
        J. Am Soc. Nephrol. 2000; 11: 1918-1925
        • Araki A.
        • Sako Y.
        Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection.
        J. Chromatogr. 1987; 422: 43-52
        • Jacques P.F.
        • Bostom A.G.
        • Selhub J.
        • et al.
        Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study.
        Atherosclerosis. 2003; 166: 49-55
        • Frosst P.
        • Blom H.J.
        • Milos R.
        • et al.
        A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter].
        Nat Genet. 1995; 10: 111-113
        • van der Put N.M.J.
        • Gabreëls F.
        • Stevens E.M.B.
        • et al.
        A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?.
        Am J. Hum Genet. 1998; 62: 1044-1051
        • Weisberg I.
        • Tran P.
        • Christensen B.
        • Sibani S.
        • Rozen R.
        A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.
        Mol. Genet Metab. 1998; 64: 169-172
        • Winkelmayer W.C.
        • Eberle C.
        • Sunder-Plassmann G.
        • Födinger M.
        Effects of the glutamate carboxypeptidase II (GCP2 1561C > T) and reduced folate carrier (RFC1 80G > A) allelic variants on folate and total homocysteine levels in kidney transplant patients.
        Kidney Int. 2003; 63: 2280-2285
        • Cockcroft D.W.
        • Gault M.H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
      1. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002:39 (Suppl 2):S1–246.

        • Zavadakova P.
        • Sokolova J.
        • Kozich V.
        Identification of novel polymorphisms and analysis of haplotypes in the methionine synthase reductase gene [abstract].
        J. Inherit Metab. Dis. 2003; 26: 36
        • Geisel J.
        • Zimbelmann I.
        • Schorr H.
        • Knapp J.P.
        • Bodis M.
        • Hübner U.
        • Herrmann W.
        Genetic defects as important factors for moderate hyperhomocysteinemia.
        Clin. Chem. Lab Med. 2001; 39: 698-704
        • Brown C.A.
        • McKinney K.Q.
        • Kaufman J.S.
        • Gravel R.A.
        • Rozen R.
        A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease.
        J. Cardiovasc. Risk. 2000; 7: 197-200
        • Ray J.G.
        • Langman L.J.
        • Vermeulen M.J.
        • Evrovski J.
        • Yeo E.L.
        • Cole D.E.C.
        Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women.
        Curr. Control Trials Cardiovasc. Med. 2001; 2: 141-149
        • Kluijtmans L.A.J.
        • Young I.S.
        • Boreham C.A.
        • et al.
        Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.
        Blood. 2003; 101: 2483-2488
        • Gaughan D.J.
        • Kluijtmans L.A.J.
        • Barbaux S.
        • et al.
        The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations.
        Atherosclerosis. 2001; 157: 451-456
        • Gaughan D.J.
        • Kluijtmans L.A.J.
        • Barbaux S.
        • et al.
        Corrigendum to “The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations” [Atherosclerosis 157 (2001) 451–456].
        Atherosclerosis. 2002; 167: 373